rss
Br J Ophthalmol 2005;89:1221 doi:10.1136/bjo.2004.063339
  • Letter

Treatment of biopsy proved conjunctival intraepithelial neoplasia with topical interferon alfa-2b

  1. S Esquenazi1,2,
  2. C L Fry1,2,
  3. E Holley1,2
  1. 1Department of Ophthalmology, Louisiana State University Health Sciences Center, New Orleans, LA, USA
  2. 2Department of Ophthalmology, Ochsner Clinic Foundation, New Orleans, LA, USA
  1. Correspondence to: Salomon Esquenazi MD, Department of Ophthalmology, Louisiana State University Health Sciences Center, 2020 Gravier Street, Suite B, New Orleans, LA 70112, USA; sesquelsuhsc.edu
  • Accepted 12 February 2005

Conjunctival intraepithelial neoplasia (CIN) is the most common conjunctival malignancy in the United States. It occurs in exposed areas of the bulbar conjunctiva with frequent involvement of the adjacent corneal epithelium. Recent studies1 have noted a recurrence rate of about 50% when there is pathological evidence of residual tumour in the surgical margin and a 5–33% recurrence rate with clear margins.2 We describe two cases of primary CIN successfully treated with topical INFα-2b. This chart review was conducted with a waiver from the Ochsner Clinic Foundation’s institutional review board, and conforms to HIPPA regulations.

Patient 1

A 65 year old retired welder was referred for further treatment of a partially resected CIN 1 month earlier. The patient had a long history of ultraviolet …

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Free archive
The full back archive is now available for BJO. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.